Aspirin underuse
This article was originally published in The Tan Sheet
Executive Summary
"Improvements in reported aspirin use for cardiovascular prevention were modest in the past decade and substantial treatment gaps have persisted, particularly for moderate-risk patients, including individuals with diabetes," reports Randall Stafford, MD/PhD, Stanford University, at the Society of General Internal Medicine annual meeting in Chicago May 23. Analyzing medical survey data over a 10-year period, Stafford found use by diabetics grew only from 4% to 6% between 1992 and 2001. Among high-risk patients, growth was modest as well, from 21% to 24%. "Targeted interventions may be warranted in patients with diabetes and/or multiple major CHD risk factors, as well as in at-risk subpopulations where aspirin use is lower than average"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.